Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 23980089)


Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.

Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ.

J Clin Oncol. 2013 Oct 10;31(29):3656-63. doi: 10.1200/JCO.2013.49.4344. Epub 2013 Aug 26.


DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].


The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ; ACCENT Collaborative Group.

Clin Colorectal Cancer. 2013 Sep;12(3):179-87. doi: 10.1016/j.clcc.2013.04.004. Epub 2013 Jun 27.


Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group.

J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. doi: 10.1093/jnci/djr310. Epub 2011 Oct 12.


Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ.

J Clin Oncol. 2008 May 10;26(14):2336-41. doi: 10.1200/JCO.2007.15.8261.


Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ.

J Clin Oncol. 2013 Jul 10;31(20):2600-6. doi: 10.1200/JCO.2013.49.6638. Epub 2013 Jun 3.


Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N.

J Clin Oncol. 2013 Dec 20;31(36):4512-9. doi: 10.1200/JCO.2012.47.3116. Epub 2013 Nov 12. Erratum in: J Clin Oncol. 2014 Mar 10;32(8):866.


Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.

Kornmann M, Staib L, Wiegel T, Kron M, Henne-Bruns D, Link KH, Formentini A; Study Group Oncology of Gastrointestinal Tumors (FOGT).

Clin Colorectal Cancer. 2013 Mar;12(1):54-61. doi: 10.1016/j.clcc.2012.07.005. Epub 2012 Oct 27.


Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20.


Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.


Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.

Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A.

J Clin Oncol. 2012 Sep 20;30(27):3353-60. doi: 10.1200/JCO.2012.42.5645. Epub 2012 Aug 20.


A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.

Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilas G.

BMC Med. 2011 Jan 31;9:10. doi: 10.1186/1741-7015-9-10.


A systematic overview of chemotherapy effects in colorectal cancer.

Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):282-308. Review.


Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.

Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.

Cancer. 2007 Mar 15;109(6):1082-9.


Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.

Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzioglou J, Katsohis C, Nenopoulou E, Karvounis N, Briassoulis E, Aravantinos G, Kosmidis P, Skarlos D, Pavlidis N.

Oncology. 2000 Apr;58(3):227-36.


Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.

Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D.

Semin Oncol. 2010 Feb;37(1):39-46. doi: 10.1053/j.seminoncol.2009.12.005.


Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A.

J Clin Oncol. 2007 Aug 20;25(24):3732-8.


National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.

Wolmark N, Colangelo L, Wieand S.

Semin Oncol. 2001 Feb;28(1 Suppl 1):9-13.


Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM.

Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk